Ticker League

Stock-Based Compensation for Moderna (MRNA)

As of · Reported

Metric

Latest period

$359.00M

YoY change

+12.6%

5Y CAGR

+39.0%

Peak year (2025)

$483.00M

Stock-Based Compensation history chart for Moderna (MRNA) from 2016 to 2025

Latest: $483.00M

Stock-Based Compensation growth chart for Moderna (MRNA) from 2016 to 2025

Latest: +12.6%

Stock-Based Compensation history table for Moderna (MRNA) from 2016 to 2025

  • 2025$483.00M+12.6%
  • 2024$429.00M+40.7%
  • 2023$305.00M+35.0%
  • 2022$226.00M+59.2%
  • 2021$142.00M+52.7%
  • 2020$93.00M+14.6%
  • 2019$81.12M+11.8%
  • 2018$72.56M+81.2%
  • 2017$40.05M+1.8%
  • 2016$39.36M—

Stock-Based Compensation values are taken from Moderna's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Stock-Based Compensation at Moderna (MRNA)

Stock-Based Compensation for Moderna (MRNA): headline value $359.00M · YoY +12.6%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

The 2025 reading of Moderna (MRNA) stock-based compensation is $483.00M – grew 12.6% year-over-year.

Moderna stock-based compensation has grown on net over the period, with a +39.0% compound annual growth rate over 2020–2025 (5 years).

The record annual stock-based compensation stands at $483.00M, reached in 2025; the historical low of $39.36M was recorded in 2016.

Moderna Stock-Based Compensation by Year

Moderna Stock-Based Compensation 2025: $483.00M

Moderna posted stock-based compensation of $483.00M in 2025, grew 12.6% from 2024. This figure represents the highest annual value in the available history.

Moderna Stock-Based Compensation 2024: $429.00M

In 2024, Moderna reported stock-based compensation of $429.00M, surged 40.7% from 2023.

Moderna Stock-Based Compensation 2023: $305.00M

Moderna stock-based compensation in 2023 was $305.00M, surged 35.0% from 2022.

Moderna Stock-Based Compensation 2022: $226.00M

2022's stock-based compensation for Moderna came in at $226.00M, surged 59.2% from 2021.

Moderna Stock-Based Compensation 2021: $142.00M

Moderna stock-based compensation in 2021 was $142.00M.

See more financial history for Moderna (MRNA).

Sector peers by Stock-Based Compensation

Healthcare peers of Moderna (MRNA), ranked by their latest stock-based compensation

Frequently asked questions

Moderna (MRNA) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return